Corporate Venture: More Important, More Strategic
This article was originally published in Start Up
In our third annual Life Science Venture Survey, corporate investors said they continue to focus on providing crucial capital to early-stage companies. They also reported this year that they’re being judged less strictly for the financial return they bring to their parent companies.
You may also be interested in...
Venture capitalists still might find medical devices to be among the more difficult sectors to place their money, but the overall mood of device investors is improving. Device VCs are encouraged by increasing opportunities on Wall Street along with interest from corporate investors, but limited partners and the FDA remain primary concerns.
In our second annual Life Science Venture Survey, VCs paid their respects to the importance of corporate investors right now. For their part, corporate investors, many from long-established programs, said they are bullish about making more bets in early-stage companies.
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.